In pancreatic cancer, for example, genetic silencing of ZDHHC9 was shown to sensitize tumors to anti-PD-L1 immunotherapy, effectively overcoming resistance to checkpoint blockade (32). This evidence concerns the gene CD274 and pancreatic neoplasm.